Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06220162
Other study ID # VACFORAML
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 1, 2024
Est. completion date December 1, 2026

Study information

Verified date January 2024
Source The First Affiliated Hospital of Soochow University
Contact Sheng-Li N Xue, M.D.
Phone +8651267781139
Email slxue@suda.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chidamide in combination with venetoclax and azacitidine (VAC) were expected to improve remission rate of patients following to VA regimen treatment failure.


Description:

Venetoclax and azacitidine has become the standard first-line treatment for elderly/unsuitable AML patients who can't tolerate for intense chemotherapy. However, a proportion of patients who were not able to achieve remission after failing to VA regimen and then were given the second cycle, and their rate of achieving remission was even lower. Chidamide down-regulates the expression of MCL and is expected to improve the remission rate further in combination with VA regimen.


Recruitment information / eligibility

Status Recruiting
Enrollment 32
Est. completion date December 1, 2026
Est. primary completion date December 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: Patients with AML who are not suitable for intensive chemotherapy according to the WHO diagnosis: age =60 years or age <60 years but fulfil the following criteria; 1. Age 18 to 59 years; 2. Eastern Cooperative Oncology Group (ECOG) physical status score of 2 or 3; 3. Expected survival time =3 months; 4. Or fulfilment of severe cardiac, pulmonary, hepatic, or renal disease; (A) Presence of a cardiac history of congestive heart failure, or ejection fraction = 50%, or presence of chronic stable angina; (B) Lung carbon monoxide diffusing capacity (DLCO) = 65%, or first forced expiratory volume (FEV1) = 65%; (C) Moderate hepatic impairment with total bilirubin > 1.5 to = 3.0 x upper limit of normal (ULN); (D) Creatinine clearance = 30 mL/min to < 45 mL/min; 5. Not received radiotherapy, treatment regimens other than the VA regimen, or haematopoietic stem cell transplantation within 4 weeks prior to enrolment; 6. Other comorbidities that, in the judgement of the physician, make the administration of intensive chemotherapy unsuitable; 7. Ability to understand and willingness to sign the informed consent for this trial; 8. The patient refuses intensive chemotherapy and has the willingness to accept non-intensive chemotherapy. Exclusion Criteria: 1. Patients with a history of myeloproliferative neoplasms (MPN), including myelofibrosis, thrombocythemia, polycythaemia vera, chronic granulocytic leukemia (CML) with or without BCR-ABL1 translocation, and AML or acute promyelocytic leukemia (APL) with BCR-ABL1 translocation; 2. Patients with FLT3 mutations and who were treated with targeted agents (inclusion is possible if the use of specific targeted agents is discontinued); 3. Patients with less than 50% reduction of blasts after VA regimen; 4. Patients with active CNS involvement; 5. With prior treatment with chidamide; 6. Clinically uncontrolled active infections (including bacterial, fungal or viral infections) and organ hemorrhage; 7. Pregnant or lactating women; 8. Participation in any other clinical trial within 3 months prior to VAC regimen; 9. With other malignant tumours; 10. With uncontrolled mental disorders; 11. Any other condition that, in the opinion of the investigator, makes it inappropriate to participate in this trial.

Study Design


Intervention

Drug:
chidamide in combination with venetoclax and azacitidine (VAC)
Enrolled patients were given chidamide 10 mg every day on days 1-14, azacitidine 75mg/m2 every day on days 1-7, and oral venetoclax began at 100mg on day 1 and increased stepwise over 3 days to reach the target dose of 400mg (100mg, 200mg, and 400mg) on days 1-28. Dose adjustments for concomitant venetoclax with CYP3A4 inhibitors were made according to the literature.

Locations

Country Name City State
China The First Affiliated Hospital of Soochow University Suzhou Jiangsu

Sponsors (6)

Lead Sponsor Collaborator
The First Affiliated Hospital of Soochow University Affiliated Hospital of Nantong University, First Affiliated Hospital Bengbu Medical College, Jining Medical University, Northern Jiangsu People's Hospital, The Second People's Hospital of Huai'an

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary ORR(overall response rate) ORR was calculated as the sum of CR, CRi, MLFS and PR. 1 month
Secondary OS (Overall survival) OS was defined as the time from enrollment to this study to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive. 2 years
Secondary EFS (Event-free survival) EFS was defined as the time from the initiation of CAV to treatment failure, relapse, death from any cause or the last follow-up. 2 years
Secondary Adverse events (AEs) It is evaluated and graded according to CTCAE 5.0. 2 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2